Physician profile
Anthony Hernandez
NPI 1962578476
$41,360.55
in general payments reported to CMS, 2019-2025
38 companies · $5,781 in 2025
The $5,781 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,236 · 2020: $4,190 · 2021: $6,077 · 2022: $6,764 · 2023: $6,454 · 2024: $6,859 · 2025: $5,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Honoraria: $805 · Education: $52.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,236.57 |
| Honoraria | $805.00 |
| Education | $52.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $10,393.74 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,597.58 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $3,104.38 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $3,027.78 | 2019-2025 | Livalo, Zoryve, Seglentis |
| Lilly USA, LLC | $2,603.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $2,570.99 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $2,311.57 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $2,264.99 | 2022-2025 | |
| Glaxosmithkline, LLC. | $1,580.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $1,343.89 | 2019-2024 | Xarelto |
| Horizon Therapeutics Plc | $1,340.06 | 2019-2023 | Krystexxa |
| Gilead Sciences, INC. | $907.85 | 2021-2025 | Vemlidy |
| Arbor Pharmaceuticals, INC. | $731.00 | 2019-2022 | |
| Pfizer INC. | $703.35 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $654.68 | 2020-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.